Table 1.

Correlation between SPHK1 expression and clinicopathologic characteristics of gastric cancer patients

CharacteristicsSPHK1
χ2 test PFisher's exact test P
Low or none, no. cases (%)High, no. cases (%)
Age (y)
    ≥6029 (48.3)54 (47.0)0.8630.875
    <6031 (51.7)61 (53.0)
Gender
    Male38 (63.3)87 (75.7)0.0880.112
    Female22 (36.7)28 (24.3)
Clinical stage
    I5 (8.3)0 (0.0)0.0030.002
    II12 (20.0)21 (18.3)
    III39 (65.0)71 (61.7)
    IV4 (6.7)23 (20.0)
T classification
    T15 (8.3)2 (1.7)0.0350.035
    T217 (28.4)20 (17.4)
    T39 (15.0)17 (14.8)
    T429 (48.3)76 (66.1)
N classification
    N019 (31.7)22 (19.1)0.0990.104
    N115 (25.0)39 (33.9)
    N2N326 (43.3)49 (42.6)
    N30 (0.0)5 (4.3)
Metastasis
    No56 (93.3)92 (80.0)0.0200.026
    Yes4 (6.7)23 (20.0)
Pathologic differentiation
    No (undifferentiated)0 (0.0)4 (3.5)0.1440.300
    Yes (differentiated)60 (100.0)111 (96.5)
Venous invasion
    No60 (100.0)107 (93.0)0.0370.032
    Yes0 (0.0)8 (7.0)
Lymphatic invasion
    No20 (33.3)40 (34.8)0.8480.869
    Yes40 (66.7)75 (65.2)